echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > NEJM: Sotorasib treatment of KRASp.G12C mutant advanced non-small cell lung cancer Phase II clinical data is gratifying

    NEJM: Sotorasib treatment of KRASp.G12C mutant advanced non-small cell lung cancer Phase II clinical data is gratifying

    • Last Update: 2021-06-16
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    In recent years, thanks to targeted drugs and immunotherapy , significant progress has been made in the treatment of non-small cell lung cancer ( NSCLC ), and the mortality rate of patients has dropped significantly.


    Immune NSCLC researchers recently announced the Phase II clinical study data of Sotorasib in the treatment of advanced NSCLC patients with KRAS p.


    In this single-center phase II trial, the researchers investigated the efficacy of Sotorasib on advanced NSCLC patients with KRAS p.


    Of the 126 patients, most (81.


    46 patients responded to the treatment (37.


    Progression-free survival after Sotorasib treatment, overall survival data

    Studies believe that Sotorasib has shown good therapeutic effects and good safety in KRASp.


    Sotorasib has shown good therapeutic effect and good safety in KRASp.


    Original source:

    Ferdinandos Skoulidis et al.


    Sotorasib for Lung Cancers with KRAS p.
    G12C Mutation.


    Leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.